Zacks Investment Research on MSN7d
Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...
Hosted on MSN1mon
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
Sales of the influenza vaccine, Fluarix, rose 14%. Sales of Established vaccines improved 8%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine, which was co ...
pharmaphorum1y
Moderna eyes 2025 approval for COVID, flu combination jab
The mRNA-1083 generated an equivalent or better immunological response compared to current flu vaccines, matching GSK’s Fluarix Quadrivalent in adults aged 50 to 64 and outperforming Sanofi’s ...
Medscape1mon
Immunogenicity and Safety of Inactivated Quadrivalent and Trivalent Influenza Vaccines in Children 18–47 Months of Age
Fluarixâ„¢, GlaxoSmithKline Vaccines) in primed and unprimed cohorts of children aged from 18 to 47 months. The main aim of the study was to assess the non-inferiority of HI antibody responses ...
Nasdaq7d
Glaxo (GSK) Up 8% Since Last Earnings Report: Can It Continue?
Sales of the influenza vaccine, Fluarix, rose 14%. Sales of Established vaccines improved 8%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine co-developed in ...